| Therapeutic | Utomilumab |
| Target | TNFRSF9 |
| Heavy Chain | EVQLVQSGAEVKKPGESLRISCKGSGYSFSTYWISWVRQMPGKGLEWMGKIYPGDSYTNYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGYGIFDYWGQGTLVTVSS |
| Light Chain | SYELTQPPSVSVSPGQTASITCSGDNIGDQYAHWYQQKPGQSPVLVIYQDKNRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCATYTGFGSLAVFGGGTKLTVL |
| 100% seqID Fv Structure | 6a3w [Fvs: AB, DE, GH, JK], 6mi2 [Fvs: AB, DE] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 6a3w [Fvs: AB, DE, GH, JK] |
| 100% seqID Structure | 6mi2 [Fvs: AB, DE] |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G2 |
| Highest Clinical Trial (June '19) | Phase-II |
| Estimated Status (June '19) | Active |
| Recorded Developmental Technology | MorphoSys HuCAL Phage Display |
| INN Year Proposed | 2016 |
| INN Year Recommended | 2017 |
| Companies Involved | Dana-Farber Cancer Institute, Immatics US, Kite Pharma, Kyowa Hakko Kirin, M. D. Anderson Cancer Center, Pfizer |
| Conditions Approved | na |
| Conditions Active | Breast cancer, Oropharyngeal cancer, Solid tumours, B-cell lymphoma, Diffuse large B cell lymphoma, Colorectal cancer, Follicular lymphoma, Ovarian cancer |
| Conditions Discontinued | Non-Hodgkin's lymphoma |
| Notes |
